[Translated article] Relationship between lactate dehydrogenase and survival in patients with non-small-cell lung cancer receiving immunotherapy

IF 1.3 Q4 PHARMACOLOGY & PHARMACY FARMACIA HOSPITALARIA Pub Date : 2025-05-01 Epub Date: 2025-01-29 DOI:10.1016/j.farma.2024.11.007
Claudia Rosique-Aznar , Alejandro Valcuende-Rosique , Dolores Rosique-Robles , Agustín Sánchez-Alcaraz
{"title":"[Translated article] Relationship between lactate dehydrogenase and survival in patients with non-small-cell lung cancer receiving immunotherapy","authors":"Claudia Rosique-Aznar ,&nbsp;Alejandro Valcuende-Rosique ,&nbsp;Dolores Rosique-Robles ,&nbsp;Agustín Sánchez-Alcaraz","doi":"10.1016/j.farma.2024.11.007","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>The expression level of programmed death ligand 1 (PD-L1) is the only approved biomarker for predicting response to immunotherapy, yet its efficacy is not always consistent. Lactate dehydrogenase (LDH) has been associated with tumor aggressiveness and poorer prognosis across various cancer types and may serve as a useful biomarker for monitoring treatment response. The objective of this study is to analyze the relationship between LDH levels prior to the start of treatment with immune checkpoint inhibitors (ICIs) and clinical outcomes in patients with non-small cell lung cancer (NSCLC).</div></div><div><h3>Method</h3><div>A retrospective study was conducted including patients diagnosed with NSCLC who were treated with at least 3 cycles of immunotherapy. Data on demographics, clinical and pathological characteristics, treatment received, pretreatment LDH levels, and clinical outcomes such as treatment response and overall survival (OS) were analyzed.</div></div><div><h3>Results</h3><div>A total of 181 patients diagnosed with NSCLC were included. Elevated pretreatment LDH levels (&gt;<!--> <!-->244 U/L) were associated with significantly reduced OS. The median survival was 548 days in patients with LDH ≤ 244 U/L, compared to 332 days in those with LDH &gt; 244 U/L (<em>P</em> = .037). Among men, OS was greater in the LDH ≤ 244 U/L group (623 days) versus 332 days in the LDH &gt; 244 U/L group (<em>P</em> = 0.043). In patients with metastatic disease, OS was higher in those with LDH ≤ 244 U/L (474 days) compared to 249 days in those with LDH &gt; 244 U/L (<em>P</em> = .023). In patients receiving both immunotherapy and chemotherapy, OS was greater in those with LDH ≤ 244 U/L (623 days) compared to 281 days in the LDH &gt; 244 U/L group (<em>P</em> = .042).</div></div><div><h3>Conclusions</h3><div>High levels of LDH prior to the start of treatment with ICIs are associated with lower treatment efficacy and a worse prognosis of the disease, especially in male, metastatic patients with a PD-L1 expression level &lt;<!--> <!-->1%.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"49 3","pages":"Pages T143-T147"},"PeriodicalIF":1.3000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"FARMACIA HOSPITALARIA","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1130634324001909","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/29 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective

The expression level of programmed death ligand 1 (PD-L1) is the only approved biomarker for predicting response to immunotherapy, yet its efficacy is not always consistent. Lactate dehydrogenase (LDH) has been associated with tumor aggressiveness and poorer prognosis across various cancer types and may serve as a useful biomarker for monitoring treatment response. The objective of this study is to analyze the relationship between LDH levels prior to the start of treatment with immune checkpoint inhibitors (ICIs) and clinical outcomes in patients with non-small cell lung cancer (NSCLC).

Method

A retrospective study was conducted including patients diagnosed with NSCLC who were treated with at least 3 cycles of immunotherapy. Data on demographics, clinical and pathological characteristics, treatment received, pretreatment LDH levels, and clinical outcomes such as treatment response and overall survival (OS) were analyzed.

Results

A total of 181 patients diagnosed with NSCLC were included. Elevated pretreatment LDH levels (> 244 U/L) were associated with significantly reduced OS. The median survival was 548 days in patients with LDH ≤ 244 U/L, compared to 332 days in those with LDH > 244 U/L (P = .037). Among men, OS was greater in the LDH ≤ 244 U/L group (623 days) versus 332 days in the LDH > 244 U/L group (P = 0.043). In patients with metastatic disease, OS was higher in those with LDH ≤ 244 U/L (474 days) compared to 249 days in those with LDH > 244 U/L (P = .023). In patients receiving both immunotherapy and chemotherapy, OS was greater in those with LDH ≤ 244 U/L (623 days) compared to 281 days in the LDH > 244 U/L group (P = .042).

Conclusions

High levels of LDH prior to the start of treatment with ICIs are associated with lower treatment efficacy and a worse prognosis of the disease, especially in male, metastatic patients with a PD-L1 expression level < 1%.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
非小细胞肺癌患者接受免疫治疗后乳酸脱氢酶与生存率的关系
目的:程序性死亡配体1 (PD-L1)的表达水平是唯一被批准用于预测免疫治疗反应的生物标志物,但其疗效并不总是一致的。乳酸脱氢酶(LDH)与各种癌症类型的肿瘤侵袭性和不良预后相关,可作为监测治疗反应的有用生物标志物。本研究的目的是分析非小细胞肺癌(NSCLC)患者开始使用免疫检查点抑制剂(ICIs)治疗前的LDH水平与临床结局之间的关系。方法:回顾性研究诊断为NSCLC且接受至少3个周期免疫治疗的患者。分析患者的人口统计学、临床和病理特征、接受的治疗、预处理LDH水平以及治疗反应和总生存期(OS)等临床结果数据。结果:共纳入181例确诊为NSCLC的患者。预处理LDH水平升高(>244 U/L)与OS显著降低相关。生存中值为548 天LDH患者 ≤  244 U / L, 332 天相比那些LDH >  244 U / L (P = .037)。男性,操作系统更大的LDH ≤  244 U / L组(623 天)和332 天LDH >  244 U / L组(P = 0.043)。转移性疾病患者,操作系统在那些与LDH ≤  244 U / L(474 天)比249年 天那些LDH >  244 U / L (P = 0)。在接受免疫治疗和化疗的病人,操作系统是在那些LDH ≤  244 U / L(623 天)比281年 天LDH >  244 U / L组(P = .042)。结论:在开始使用ICIs治疗之前,高水平的LDH与较低的治疗效果和较差的疾病预后相关,特别是在PD-L1表达水平的男性转移性患者中
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
FARMACIA HOSPITALARIA
FARMACIA HOSPITALARIA PHARMACOLOGY & PHARMACY-
CiteScore
1.90
自引率
21.40%
发文量
46
审稿时长
37 days
期刊介绍: Una gran revista para acceder a los mejores artículos originales y revisiones de la farmacoterapia actual. Además, es Órgano de expresión científica de la Sociedad Española de Farmacia Hospitalaria, y está indexada en Index Medicus/Medline, EMBASE/Excerpta Médica, Alert, Internacional Pharmaceutical Abstracts y SCOPUS.
期刊最新文献
Risk factors for emergency department revisit among elderly patients with gastrointestinal bleeding secondary to oral anticoagulant therapy. Sterility of repackaged faricimab for intravitreal administration. Telepharmacy follow-up using electronic patient-reported outcome measures in moderate-to-severe psoriasis. [Translated article] Professional profile and expectations of members associated to Pharmaceutical Care in Infectious Diseases group of the Spanish Society of Hospital Pharmacy. Methodological interpretation of subgroup analysis by histological subtype for perioperative toripalimab in resectable non-small-cell lung cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1